University of Iowa researchers are leading a national vaccine trial, to battle the inflammatory virus chickungunya.
It's a virus that's long been in East Africa, more recently it's been in the Caribbean.
Health experts say the mosquito-borne virus has affected more than two (M) million people in the Americas in the last few years. It's been detected in the US since 2014.
It's rarely fatal, but it can cause an intense inflammatory reaction, resulting in severe join pain, fever, rash and lingering symptoms.
Researchers will enroll healthy adult volunteers to participate in the Phase 1/2 trial, which is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is being conducted at several NIAID-funded Vaccine and Treatment Evaluation Units.
For more information on the study click HERE.